Kiltearn Medical Centre

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Type 2 diabetes5 trials
• Psoriasis1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Novo Nordisk A/S4 trials
• Pfizer2 trials
• Arctic Bioscience1 trial
• Boehringer Ingelheim1 trial

Running trials

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  NCT07931599· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Recruiting

  AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  NCT07339423· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

  NCT06125808· Phase 2· Arctic Bioscience· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source